BMS-986489: No Evidence for Clinical Use
There is no available evidence for the clinical use of BMS-986489 (also known as Beclabuvir) in the provided literature, and no guidelines or drug labels support its current use in clinical practice.
Available Evidence on Related BMS Compounds
The search yielded information on several other BMS-numbered investigational compounds, but none specifically address BMS-986489:
BMS Compounds with Discontinued Development
BMS-986094 (guanosine nucleotide analogue prodrug) was withdrawn from clinical trials due to serious safety issues, though subsequent investigations suggested it was not a direct mitochondrial toxicant 1
BMS-986001 (thymidine analogue NRTI for HIV-1) showed similar efficacy to tenofovir but was associated with greater resistance mutations and increased fat accumulation, leading Bristol-Myers Squibb to discontinue development 2
BMS-986020 (LPA1 antagonist for idiopathic pulmonary fibrosis) was discontinued after Phase 2 trials revealed hepatobiliary toxicity including elevated liver enzymes, cholecystitis, and bile duct pathology 3
BMS-986260 (TGFβRI inhibitor) development was terminated due to cardiovascular toxicity, specifically valvulopathy, that could not be adequately mitigated even with intermittent dosing schedules 4
BMS Compounds in Active Development
- BMS-986408 is a dual DGKα/DGKζ inhibitor currently in clinical-stage development for cancer immunotherapy, showing promise in combination with PD-1 checkpoint inhibitors and CAR T-cell therapy 5
Clinical Implications
If you are seeking information about BMS-986489 specifically, you should:
- Verify the correct compound designation, as it may be referenced under a different identifier or chemical name
- Contact the manufacturer directly for any available investigational data
- Consider whether you meant to inquire about one of the other BMS compounds listed above
- Recognize that absence of published evidence typically indicates either very early-stage development, discontinued development, or that the compound designation may be incorrect
No clinical recommendations can be made for BMS-986489 given the complete absence of published evidence regarding its safety, efficacy, or appropriate use in any medical condition.